Navigation Links
Amgen And Cytokinetics Announce The First Presentation Of Data From Phase 2 ATOMIC-AHF Study Of Omecamtiv Mecarbil
Date:9/2/2013

nally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and products liability claims. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development.

In addition, sales of our products are affected by the reimbursement policies imposed by third-party payors, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products. In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products. We believe that some of our newer products, product candidates or new indications for existing products, may face competition when and as they are approved and marketed. Our products may compete against products that have lower prices, established reimbursement, superior performance, are easier to administer, or that are otherwise competitive with our products. In addition, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications ma
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Amgen To Participate At Citis 8th Annual Biotech Conference
2. Healthcare Briefing - Leading Medical Companies in the News: Bio-Solutions, Catalyst Pharmaceutical, MannKind, Amgen, Accuray
3. Amgen to Highlight New Data at Upcoming ESC Congress 2013
4. Acquisition of Onyx Pharmaceuticals, Inc. by Amgen Inc. May Not Be in the Best Interests of Onyx Pharmaceuticals, Inc. Shareholders
5. Amgen To Acquire Onyx Pharmaceuticals For $125 Per Share In Cash
6. Morning Research: BioCryst Pharma Inc., Questcor Pharma Inc., PDL BioPharma Inc., and Amgen Inc.
7. Amgens Second Quarter 2013 Revenues Increased 5 Percent To $4.7 Billion And Adjusted Earnings Per Share (EPS) Increased 3 Percent To $1.89
8. Amgen Announces Webcast of 2013 Second Quarter Financial Results
9. Amgen Award For Science Teaching Excellence Honors Outstanding Teachers
10. Amgen Announces Top-Line Results Of Phase 3 Trebananib (AMG 386) TRINOVA-1 Trial In Recurrent Ovarian Cancer
11. Amgen Presents Positive Results From Talimogene Laherparepvec Phase 3 Study In Patients With Metastatic Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... 22, 2015  China Nepstar Chain Drugstore Ltd. (NYSE: ... drugstore chain in China based ... the resignation of Mr. Fuxiang Zhang as ... immediately. Ms. Rebecca Yingnan Zhang has been ... of directors, effective immediately. Meanwhile, Ms. Zhang resigned from ...
(Date:5/21/2015)... Research and Markets ... of the "Arthroscopy Devices Markets Worldwide" ... http://photos.prnewswire.com/prnh/20130307/600769) , ,The purpose of this report ... market for Arthroscopy Devices. The report discusses ... market for these products. , ,Product - ...
(Date:5/21/2015)... , 21. Mai 2015 ... ), ein Unternehmen für Arzneimittel im ... Entwicklung und Vermarktung von Locilex® (Pexiganan-Creme ... heute eine wissenschaftliche Posterpräsentation an, welche ... Unternehmens vorstellt, OneStep-1 und OneStep-2, in ...
Breaking Medicine Technology:China Nepstar Chain Drugstore Ltd. Announces Management Change and New Director Appointment 2China Nepstar Chain Drugstore Ltd. Announces Management Change and New Director Appointment 3Analysing Arthroscopy Devices Markets Worldwide 2014-2020 2Analysing Arthroscopy Devices Markets Worldwide 2014-2020 3Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 2Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 3Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 4Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 5Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 6Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 7
... 2011 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) ... BMN 673, a poly ADP-ribose polymerase (PARP) inhibitor in development ... inihibtors have been validated to show survival benefits in cancer ... in combination with DNA damaging agents, and BMN 673 appears ...
... 2011 Virtual Radiologic (vRad), a technology-enabled national radiology ... the Teleradiology Services market segment by independent research and ... customer surveys and interviews conducted by KLAS and is ... in KLAS Awards: Software & Professional Services report. ...
Cached Medicine Technology:BioMarin Initiates Phase 1/2 Trial for BMN 673 for the Treatment of Genetically-Defined Cancers 2BioMarin Initiates Phase 1/2 Trial for BMN 673 for the Treatment of Genetically-Defined Cancers 3Virtual Radiologic Ranked #1 for Teleradiology Services for Third Consecutive Year 2
(Date:5/23/2015)... With the implementation of the Affordable ... increasingly difficult to provide their employees with a viable ... insurance for employees stand to face strict penalties. Never ... part of a business’s success or failure. In an ... USA Doctors has created a varying level of less ...
(Date:5/23/2015)... Javon Bea Mercy Health System CEO ... Center, 557 N. Washington St., Janesville, will host an ... pm. , The 8-week clinic is lead by Brent ... who will offer training that encompasses a warm-up, training ... show selection and weekly training plans. , The program ...
(Date:5/22/2015)... 22, 2015 The American College of ... in June. They will hold a webinar on the ... two-day class on Classical Chinese Medicine. , Webinar – ... Steve Given, the Dean of Clinical Education, will lead ... First Professional Doctorate program. ACTCM is currently developing this ...
(Date:5/22/2015)... Omar Ahmad Barrada, a junior at Milton ... 2015 Congress of Future Medical Leaders in Boston, Mass. ... “America’s highest achieving high school students.” , “I’m excited ... goals and learn better study habits,” said Omar. “The ... we can ask the surgeons questions.” , The goal ...
(Date:5/22/2015)... Carnegie Science Center and ... new partnership to develop BodyTech, a dynamic, three-pronged health ... includes a new exhibit at the Science Center called ... a new traveling science show, Anatomy Adventure, which will ... , Designed to explore a wide range of topics ...
Breaking Medicine News(10 mins):Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 2Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 3Health News:ACTCM Announces Upcoming June Events 2Health News:Milton Hershey School Student Chosen for Congress of Future Medical Leaders 2Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 2Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 3Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 4
... Provides Update on Oncology Pipeline Progress, SAN DIEGO, ... announced financial results for the three and nine,months ended ... 30,2007, the Company posted revenues of $7.6 million and ... ended September 30, 2007, revenues were $27.1,million and the ...
... Human Vaccine Against West Nile Virus Today; ... Disease Endemic in the United States, ... of sanofi-aventis Group, announced today that it has,signed an exclusive ... of a West Nile vaccine to help fight against,this serious, ...
... urinary levels of certain molecules might have the potential ... ailment caused by the autoimmune disease lupus, UT Southwestern ... a quartet of molecules may have potential diagnostic significance, ... senior author of a study available online at the ...
... CRME TSX: COM, VANCOUVER, Nov. 12 /PRNewswire-FirstCall/ - ... that it will report 2007 third,quarter financial results on ... a teleconference call and webcast at 4:30pm Eastern Time,(1:30pm ... To access the conference call, please dial 416-340-8010 ...
... Nov. 12 ,Seeking to expand Indo-U.S. healthcare ... Healthy India launched its inaugural,executive mission to ... from the,most prominent players in healthcare, including: ... Avesthagen, Excel Life Sciences,Cognizant, Stryker, BD, Yes ...
... plaguing inner-city youth at epidemic rates, the report of ... Journal of the American College of Surgeons illustrated a ... study showed that Caught in the Crossfire, a hospital-based ... system among youth aged 12 to 20. Additionally, ...
Cached Medicine News:Health News:SGX Pharmaceuticals Announces Financial Results for the Three and Nine Months Ended September 30, 2007 2Health News:SGX Pharmaceuticals Announces Financial Results for the Three and Nine Months Ended September 30, 2007 3Health News:SGX Pharmaceuticals Announces Financial Results for the Three and Nine Months Ended September 30, 2007 4Health News:SGX Pharmaceuticals Announces Financial Results for the Three and Nine Months Ended September 30, 2007 5Health News:SGX Pharmaceuticals Announces Financial Results for the Three and Nine Months Ended September 30, 2007 6Health News:SGX Pharmaceuticals Announces Financial Results for the Three and Nine Months Ended September 30, 2007 7Health News:SGX Pharmaceuticals Announces Financial Results for the Three and Nine Months Ended September 30, 2007 8Health News:Sanofi Pasteur and Acambis Join Forces to Bring West Nile Vaccine to Market 2Health News:Sanofi Pasteur and Acambis Join Forces to Bring West Nile Vaccine to Market 3Health News:Sanofi Pasteur and Acambis Join Forces to Bring West Nile Vaccine to Market 4Health News:Researchers investigate ways to detect lupus-associated kidney disease 2Health News:Cardiome To Release Third Quarter Results 2Health News:Cardiome To Release Third Quarter Results 3Health News:USIBC Launches Healthcare Mission to India 2Health News:Study quantifies cost-benefit of hospital-based program to keep youth out of prison 2Health News:Study quantifies cost-benefit of hospital-based program to keep youth out of prison 3
Meyerding Laminectomy Retractors, self-retaining....
Scoville-Haverfield Hemilaminectomy Retractor...
Bookwalter Spinal Retractor...
Circular Spine Retractor System for microsurgical interventions in the lumbar and cervical spine region....
Medicine Products: